Hexarelin
Hexarelin
Potent GHRP with cardiac protective properties. Strong GH release with cardioprotective benefits.
Save 10% when you pay in crypto (BTC · ETH · USDT)
Free shipping on orders over $250
Research use only. Products are not intended for human consumption.
We accept
Interac e-Transfer · BTC · ETH · USDT crypto −10%
How ordering works
- 01Place your order — no payment is taken on this site.
- 02Payment instructions arrive by email reply (Interac e-Transfer or crypto).
- 03Paid before 4 PM EST → same-day dispatch with tracking number.
Refrigerated SKU? Ships in an insulated cold-pack mailer. You receive a packaging photograph within 4 hours of dispatch.
- Janoshik verified — per-batch third-party purity testing
- Discreet — plain packaging, no brand markings
- Cold-pack mailer for refrigerated SKUs
- Refund + retest if a batch fails purity
Complete protocols
Build your stack
Stacks that include Hexarelin — protocol components priced together, bulk savings applied automatically.
At a glance
At a glance
- Concentration
- 5mg
- Purity
- 99.5%+
- Route
- Subcutaneous injection
- Storage
- Lyophilized: room temperature, desiccated. Reconstituted: 2–8°C, ≤30 days.
Compound profile
Hexarelin (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide GHRP and one of the most potent growth hormone secretagogues ever developed. It produces the strongest acute GH release of any GHRP — surpassing GHRP-6, GHRP-2, and Ipamorelin — making it the compound of choice for researchers investigating maximal GH stimulation. What distinguishes hexarelin from other GHRPs, however, is not just its GH-releasing potency but its documented cardioprotective properties — an effect mediated through a non-GHS-R1a mechanism unique to this compound.
Hexarelin (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide GHRP and one of the most potent growth hormone secretagogues ever developed. It produces the strongest acute GH release of any GHRP — surpassing GHRP-6, GHRP-2, and Ipamorelin — making it the compound of choice for researchers investigating maximal GH stimulation. What distinguishes hexarelin from other GHRPs, however, is not just its GH-releasing potency but its documented cardioprotective properties — an effect mediated through a non-GHS-R1a mechanism unique to this compound.
Hexarelin activates the GHS-R1a receptor with exceptionally high affinity, producing acute GH elevations of 10-20 fold above baseline — the highest of any peptide-based secretagogue. However, hexarelin also binds to CD36 (scavenger receptor class B member 3), a receptor expressed on cardiac myocytes and coronary vasculature. This CD36-mediated pathway produces cardioprotective effects independent of GH release: reduced cardiac fibrosis, improved left ventricular function, decreased infarct size following ischemic events, and anti-atherosclerotic activity through modulation of macrophage cholesterol efflux. These cardiac effects occur at doses lower than those needed for maximal GH release, suggesting the two activities can be separately optimized.
Research on hexarelin's GH-releasing properties documents the strongest acute response of any GHRP, but also the most pronounced desensitization. Continuous daily use at high doses leads to diminished GH response within 4-8 weeks due to receptor downregulation — a limitation not shared by Ipamorelin or GHRP-2 to the same degree. The cardiovascular research, however, shows sustained benefit: studies in ischemia-reperfusion models document reduced myocardial damage, preserved ejection fraction, and anti-fibrotic effects. This dual profile — potent but desensitization-prone GH release plus sustained cardiac protection — makes hexarelin a unique compound in the GHRP class.
Hexarelin is best suited for researchers investigating maximal GH stimulation in short-term protocols, cardioprotective peptide mechanisms, and cardiac recovery. Researchers using hexarelin for GH purposes should plan for cyclical dosing (4 weeks on, 2-4 weeks off) to manage receptor desensitization. Those primarily interested in its cardioprotective effects may use lower doses continuously.
Reconstitute with 2.5ml bacteriostatic water (yielding 2mg/ml). Administer via subcutaneous injection, 100-200mcg per dose, 1-3 times daily. Inject on an empty stomach. Hexarelin produces a noticeable appetite increase (between GHRP-2 and GHRP-6 in magnitude) and mild transient cortisol and prolactin elevation. Half-life is approximately 70 minutes. Store at 2-8C after reconstitution. Due to desensitization potential, cycle protocols rather than continuous use.
---
## Growth Factors
How to use
Injection technique, site rotation, and frequency guidance. Typical protocols split the weekly dose into 2 injections.
Hexarelin is supplied as a lyophilized (freeze-dried) powder and must be reconstituted with bacteriostatic water (BAC water) before use in a research setting.
- Clean the BAC water vial stopper and the peptide vial stopper with an alcohol swab. Allow to dry.
- Draw the required volume of BAC water into a sterile syringe (typically 1–3 mL depending on target concentration).
- Angle the needle so the water runs down the inside wall of the peptide vial. Avoid dispensing directly onto the powder.
- Do not shake. Gently swirl or roll until fully dissolved. Vigorous shaking can denature peptides.
- Refrigerate reconstituted solution at 2–8°C. Most reconstituted peptides are stable 14–30 days depending on compound.
Target concentration determines drawing volume. For dosing math, consult the dosing math guide.
Independent lab verification
Research disclaimer
For research and laboratory use only. Not for human or veterinary consumption. Nova Pharma sells to qualified researchers of legal age and ships to Canadian addresses only. See disclaimer and terms.
At a glance
At a glance
- Concentration
- 5mg
- Purity
- 99.5%+
- Route
- Subcutaneous injection
- Storage
- Lyophilized: room temperature, desiccated. Reconstituted: 2–8°C, ≤30 days.
Compound profile
Hexarelin (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide GHRP and one of the most potent growth hormone secretagogues ever developed. It produces the strongest acute GH release of any GHRP — surpassing GHRP-6, GHRP-2, and Ipamorelin — making it the compound of choice for researchers investigating maximal GH stimulation. What distinguishes hexarelin from other GHRPs, however, is not just its GH-releasing potency but its documented cardioprotective properties — an effect mediated through a non-GHS-R1a mechanism unique to this compound.
Hexarelin (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide GHRP and one of the most potent growth hormone secretagogues ever developed. It produces the strongest acute GH release of any GHRP — surpassing GHRP-6, GHRP-2, and Ipamorelin — making it the compound of choice for researchers investigating maximal GH stimulation. What distinguishes hexarelin from other GHRPs, however, is not just its GH-releasing potency but its documented cardioprotective properties — an effect mediated through a non-GHS-R1a mechanism unique to this compound.
Hexarelin activates the GHS-R1a receptor with exceptionally high affinity, producing acute GH elevations of 10-20 fold above baseline — the highest of any peptide-based secretagogue. However, hexarelin also binds to CD36 (scavenger receptor class B member 3), a receptor expressed on cardiac myocytes and coronary vasculature. This CD36-mediated pathway produces cardioprotective effects independent of GH release: reduced cardiac fibrosis, improved left ventricular function, decreased infarct size following ischemic events, and anti-atherosclerotic activity through modulation of macrophage cholesterol efflux. These cardiac effects occur at doses lower than those needed for maximal GH release, suggesting the two activities can be separately optimized.
Research on hexarelin's GH-releasing properties documents the strongest acute response of any GHRP, but also the most pronounced desensitization. Continuous daily use at high doses leads to diminished GH response within 4-8 weeks due to receptor downregulation — a limitation not shared by Ipamorelin or GHRP-2 to the same degree. The cardiovascular research, however, shows sustained benefit: studies in ischemia-reperfusion models document reduced myocardial damage, preserved ejection fraction, and anti-fibrotic effects. This dual profile — potent but desensitization-prone GH release plus sustained cardiac protection — makes hexarelin a unique compound in the GHRP class.
Hexarelin is best suited for researchers investigating maximal GH stimulation in short-term protocols, cardioprotective peptide mechanisms, and cardiac recovery. Researchers using hexarelin for GH purposes should plan for cyclical dosing (4 weeks on, 2-4 weeks off) to manage receptor desensitization. Those primarily interested in its cardioprotective effects may use lower doses continuously.
Reconstitute with 2.5ml bacteriostatic water (yielding 2mg/ml). Administer via subcutaneous injection, 100-200mcg per dose, 1-3 times daily. Inject on an empty stomach. Hexarelin produces a noticeable appetite increase (between GHRP-2 and GHRP-6 in magnitude) and mild transient cortisol and prolactin elevation. Half-life is approximately 70 minutes. Store at 2-8C after reconstitution. Due to desensitization potential, cycle protocols rather than continuous use.
---
## Growth Factors
How to use
Injection technique, site rotation, and frequency guidance. Typical protocols split the weekly dose into 2 injections.
Hexarelin is supplied as a lyophilized (freeze-dried) powder and must be reconstituted with bacteriostatic water (BAC water) before use in a research setting.
- Clean the BAC water vial stopper and the peptide vial stopper with an alcohol swab. Allow to dry.
- Draw the required volume of BAC water into a sterile syringe (typically 1–3 mL depending on target concentration).
- Angle the needle so the water runs down the inside wall of the peptide vial. Avoid dispensing directly onto the powder.
- Do not shake. Gently swirl or roll until fully dissolved. Vigorous shaking can denature peptides.
- Refrigerate reconstituted solution at 2–8°C. Most reconstituted peptides are stable 14–30 days depending on compound.
Target concentration determines drawing volume. For dosing math, consult the dosing math guide.
Independent lab verification
Research disclaimer
For research and laboratory use only. Not for human or veterinary consumption. Nova Pharma sells to qualified researchers of legal age and ships to Canadian addresses only. See disclaimer and terms.
Read the research
Reference articles from the lab covering this compound.
Complete the protocol
Reconstitution Kit — Standard
30ml bac water · 10 syringes · mixing syringe · swabs
4.9
